Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06068946 · ClinicalTrials.gov registry record · Phase 2
VK2735 for Weight Management Phase 2
A Phase 2 study, sponsored by Viking Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 176
- Enrollment target
NCT06068946: Completed Phase 2 study, sponsored by Viking Therapeutics.
NCT06068946 is a Phase 2 study that has completed, run by Viking Therapeutics. The registered enrollment target is 176 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06068946, a Phase 2 study, has completed, sponsored by Viking Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 176 participants
- Enrollment target
Study Summary
This is a phase 2, 13-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults who are obese (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid condition. VK2735 or matched placebo will be administered once weekly.
Primary Outcome
To measure the efficacy of VK2735 for weight loss in adult Subjects who are obese, or overweight with at least one weight-related comorbid condition
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL VK2735
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 176 participants |
| Start Date | 2023-08-31 |
| Est. Completion | 2024-04-02 |
| Phase | Phase 2 |
What the finished NCT06068946 record still lists
NCT06068946 is an interventional study that assigns participants to a tested intervention. The registered 176 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06068946 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06068946 about?
NCT06068946 is a clinical study titled "VK2735 for Weight Management Phase 2". This is a phase 2, 13-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults who are obese (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with at...
What is the current status of trial NCT06068946?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 176 participants. The study started on 2023-08-31. Estimated completion is 2024-04-02.
What interventions are being tested in trial NCT06068946?
The interventions under investigation include: Placebo (BIOLOGICAL), VK2735 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06068946?
This trial is sponsored by Viking Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06068946's enrollment target sits among peer trials
176 394th of 2000 higher than 1,605 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03304821 · 176 participants · Phase 2
Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial Disease
- NCT03447938 · 176 participants · NA
The Minimally Invasive Coronary Surgery Compared to STernotomy Coronary Artery Bypass Grafting Trial
- NCT03824145 · 176 participants · NA
Every Day Counts: A Lifestyle Program for Women With Metastatic Breast Cancer
- NCT04177914 · 176 participants · Phase 3
HCRN Endoscopic Versus Shunt Treatment of Hydrocephalus in Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI